Please login to the form below

Not currently logged in
Email:
Password:

momelotinib

This page shows the latest momelotinib news and features for those working in and with pharma, biotech and healthcare.

Another late-stage setback tarnishes Gilead's R&D lustre

Another late-stage setback tarnishes Gilead's R&D lustre

Gilead has suffered another late-stage pipeline blow, posting lacklustre data for momelotinib – a would-be rival to Incyte/Novartis' blockbuster Jakafi/Jakavi. ... drug. A better profile against anaemia was held up as a key differentiator when Gilead

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics